Compare Sterling Biotech with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs CADILA HEALTHCARE - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH CADILA HEALTHCARE STERLING BIOTECH/
CADILA HEALTHCARE
 
P/E (TTM) x -0.4 17.3 - View Chart
P/BV x 0.0 2.3 0.6% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 STERLING BIOTECH   CADILA HEALTHCARE
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
CADILA HEALTHCARE
Mar-19
STERLING BIOTECH/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs11432 2.4%   
Low Rs3306 1.1%   
Sales per share (Unadj.) Rs26.8128.6 20.8%  
Earnings per share (Unadj.) Rs-15.018.5 -80.6%  
Cash flow per share (Unadj.) Rs-5.524.4 -22.4%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs54.9101.5 54.1%  
Shares outstanding (eoy) m267.871,023.74 26.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 9.0%   
Avg P/E ratio x-0.519.9 -2.3%  
P/CF ratio (eoy) x-1.315.1 -8.4%  
Price / Book Value ratio x0.13.6 3.5%  
Dividend payout %018.9 0.0%   
Avg Mkt Cap Rs m1,862378,170 0.5%   
No. of employees `0001.412.4 10.9%   
Total wages/salary Rs m54721,241 2.6%   
Avg. sales/employee Rs Th5,303.310,585.0 50.1%   
Avg. wages/employee Rs Th403.81,707.8 23.6%   
Avg. net profit/employee Rs Th-2,959.01,526.5 -193.8%   
INCOME DATA
Net Sales Rs m7,181131,656 5.5%  
Other income Rs m432,011 2.1%   
Total revenues Rs m7,223133,667 5.4%   
Gross profit Rs m94729,731 3.2%  
Depreciation Rs m2,5435,986 42.5%   
Interest Rs m4,3771,935 226.2%   
Profit before tax Rs m-5,93123,821 -24.9%   
Minority Interest Rs m0469 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9245,303 -36.3%   
Profit after tax Rs m-4,00718,987 -21.1%  
Gross profit margin %13.222.6 58.4%  
Effective tax rate %32.422.3 145.7%   
Net profit margin %-55.814.4 -386.9%  
BALANCE SHEET DATA
Current assets Rs m14,33584,981 16.9%   
Current liabilities Rs m49,80973,425 67.8%   
Net working cap to sales %-494.08.8 -5,628.3%  
Current ratio x0.31.2 24.9%  
Inventory Days Days40375 541.3%  
Debtors Days Days171110 155.8%  
Net fixed assets Rs m55,432133,493 41.5%   
Share capital Rs m2681,024 26.2%   
"Free" reserves Rs m13,935102,839 13.6%   
Net worth Rs m14,701103,863 14.2%   
Long term debt Rs m9,47839,497 24.0%   
Total assets Rs m73,988234,831 31.5%  
Interest coverage x-0.413.3 -2.7%   
Debt to equity ratio x0.60.4 169.5%  
Sales to assets ratio x0.10.6 17.3%   
Return on assets %0.58.9 5.6%  
Return on equity %-27.318.3 -149.1%  
Return on capital %-6.418.3 -35.1%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86048,404 3.8%   
Fx outflow Rs m2511,593 0.2%   
Net fx Rs m1,83536,811 5.0%   
CASH FLOW
From Operations Rs m1,71928,823 6.0%  
From Investments Rs m-3,148-57,387 5.5%  
From Financial Activity Rs m1,42618,846 7.6%  
Net Cashflow Rs m-3-7,105 0.0%  

Share Holding

Indian Promoters % 33.9 74.8 45.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.3 -  
FIIs % 9.9 5.9 167.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 11.0 357.3%  
Shareholders   21,482 44,069 48.7%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   FULFORD INDIA  SUVEN LIFESCIENCES  CIPLA  WOCKHARDT  VENUS REMEDIES  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS